Physician profile
Danielle Doedens
NPI 1144661455
$7,278.58
in general payments reported to CMS, 2019-2025
37 companies · $1,345 in 2025
The $1,345 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,954 · 2022: $1,079 · 2023: $1,171 · 2024: $1,729 · 2025: $1,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,220 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,220.42 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,301.50 | 2021-2025 | |
| Novo Nordisk INC | $894.25 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Inspire Medical Systems, INC. | $519.41 | 2023-2025 | Inspire |
| Amgen INC. | $485.17 | 2021-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $470.94 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $439.68 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $414.73 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $310.98 | 2021-2025 | |
| Abbott Laboratories | $284.66 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceuticals, INC. | $279.41 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $181.15 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.71 | 2021-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company Ltd. | $173.88 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $159.13 | 2021-2022 | |
| Exact Sciences Corporation | $119.12 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Doedens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.